C12N 2720/12041
Use of virus, viral particle or viral elements as a vector
C12N2720/12041 (Use of virus, viral particle or viral elements as a vector) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 7
- Assignees
- 4
- Inventors
- 8
- Latest grant
- 19 Sep 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2019 | 0 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 0 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2720/12043Viral genome or elements thereof as genetic vectorIndexing code4
- C12N 2720/12042Virus or viral particle as vehicleIndexing code0
- C12N 2720/12044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2720/12045Special targeting system for viral vectorsIndexing code0
Recent patents
- Human rotavirus G9P[6] strain and use as a vaccine19 Sep 2023US 11,759,513 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof13 Dec 2022US 11,525,146 B2Oisin Biotechnologies, Inc.
- Human rotavirus G9P[6] strain and use as a vaccine30 Nov 2021US 11,185,581 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Human rotavirus G9P[6] strain and use as a vaccine4 Feb 2020US 10,548,970 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof8 Oct 2026US 2026/0308635 A1Oisin Biotechnologies, Inc.
- Novel reovirus-based vaccine platform and use thereof15 May 2025US 2025/0154204 A1Virocure, Inc.
- Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell13 Jul 2023US 2023/0220422 A1Oisin Biotechnologies, Inc.
- Human rotavirus g9p[6] strain and use as a vaccine10 Feb 2022US 2022/0040288 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Human rotavirus g9p[6] strain and use as a vaccine23 Apr 2020US 2020/0121781 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.